Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions
Positive Data from INSPIRE Trial Continues to Highlight Safety and Tolerability Along with Improvement in Quality of Life Metrics from LIQ861 RESEARCH TRIANGLE PARK, N.C. , April 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical
View HTML
Toggle Summary Liquidia Technologies to Present at Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , April 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 21, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
•  LIQ861 was well-tolerated in PAH patients at two months of treatment •  INSPIRE enrollment complete, including PK sub-study •  Anticipate submitting NDA for LIQ861 to the FDA in late 2019 RESEARCH TRIANGLE PARK, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
View HTML
Toggle Summary Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trial Accepted by FDA into Emerging Technology Program to support review of PRINT ® technology Management to host webcast and conference call today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Feb.
View HTML
Toggle Summary Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019
RESEARCH TRIANGLE PARK, N.C. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDA NDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical
View HTML
Toggle Summary Liquidia Technologies Provides Leadership Update
RESEARCH TRIANGLE PARK, N.C. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML